查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420934

头颈癌市场 - 全球产业分析、规模、份额、成长、趋势和预测，2023-2031 年

Head and Neck Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 178 Pages | 商品交期: 2-10个工作天内

价格

头颈癌市场 - 报告范围

TMR 关于全球头颈癌市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球头颈癌的收入2017-2031 年颈部癌症市场，以2023 年为基准年，2031 年为预测年。报告中也提供了2023年至2031年全球头颈癌市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解头颈癌市场。

市场概况
2023年市场价值 16 亿美元
2031 年市场价值 29亿美元
CAGR 6.8%

该报告深入研究了全球头颈癌市场的竞争格局。全球头颈癌市场的主要参与者已经确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球头颈癌市场参与者的属性。

目录

第 1 章：执行摘要

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 市场区隔
  • 概述
  • 市场动态
  • 2017-2031 年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2017-2031
    • EGFR抑制剂
    • 有丝分裂抑制剂
    • 抗PD-1单株抗体
    • 其他的
  • 市场吸引力：按药品类别

第 7 章：全球市场分析与预测：按配销通路

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2017-2031
    • 医院药房
    • 零售药局
    • 电子商务
  • 市场吸引力：按配销通路

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第 14 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Sanofi
    • Pfizer
    • Eli Lilly and Company
    • F. Hoffman-La Roche
    • AstraZeneca
    • Merck KgaA
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Galera
    • Fresenius Kabi
    • Teva Pharmaceuticals
Product Code: TMRGL22919

Head and Neck Cancer Market - Scope of Report

TMR's report on the global head and neck cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global head and neck cancer market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global head and neck cancer market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the head and neck cancer market.

Market Snapshot
Market Value in 2023US$ 1.6 Bn
Market Value in 2031US$ 2.9 Bn
CAGR6.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global head and neck cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global head and neck cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global head and neck cancer market.

The report delves into the competitive landscape of the global head and neck cancer market. Key players operating in the global head and neck cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global head and neck cancer market profiled in this report.

Key Questions Answered in Global head and neck cancer Market Report:

  • What is the sales/revenue generated by head and neck cancer across all regions during the forecast period?
  • What are the opportunities in the global head and neck cancer market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Head and Neck Cancer Market - Research Objectives and Research Approach

The comprehensive report on the global head and neck cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global head and neck cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global head and neck cancer market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Head and Neck Cancer Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. EGFR Inhibitors
    • 6.3.2. Mitotic Inhibitors
    • 6.3.3. Anti-PD-1 Monoclonal Antibodies
    • 6.3.4. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospitals Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. E-commerce
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Head and Neck Cancer Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Head and Neck Cancer Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Class, 2017-2031
    • 9.2.1. EGFR Inhibitors
    • 9.2.2. Mitotic Inhibitors
    • 9.2.3. Anti-PD-1 Monoclonal Antibodies
    • 9.2.4. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. E-commerce
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Head and Neck Cancer Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. EGFR Inhibitors
    • 10.2.2. Mitotic Inhibitors
    • 10.2.3. Anti-PD-1 Monoclonal Antibodies
    • 10.2.4. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospitals Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. E-commerce
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. EGFR Inhibitors
    • 11.2.2. Mitotic Inhibitors
    • 11.2.3. Anti-PD-1 Monoclonal Antibodies
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospitals Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. E-commerce
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Head and Neck Cancer Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. EGFR Inhibitors
    • 12.2.2. Mitotic Inhibitors
    • 12.2.3. Anti-PD-1 Monoclonal Antibodies
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospitals Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. E-commerce
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. EGFR Inhibitors
    • 13.2.2. Mitotic Inhibitors
    • 13.2.3. Anti-PD-1 Monoclonal Antibodies
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospitals Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. E-commerce
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Sanofi
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Eli Lilly and Company
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. F. Hoffman-La Roche
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. AstraZeneca
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Merck KgaA
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Bayer AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Bristol-Myers Squibb Company
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Galera
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Fresenius Kabi
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Teva Pharmaceuticals
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview

List of Tables

  • Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031
  • Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017-2031

List of Figures

  • Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022
  • Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022
  • Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022-2031
  • Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023-2031
  • Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)